Bioatla Inc (BCAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioatla Inc (BCAB) has a cash flow conversion efficiency ratio of 0.141x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.27 Million) by net assets ($-37.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bioatla Inc balance sheet independence to measure how much of total assets are equity-financed.
Bioatla Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bioatla Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Bioatla Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Bioatla Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioatla Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CodeLab Capital A/S
OL:CODE
|
-0.556x |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
0.005x |
|
Philly Shipyard ASA
OL:PHLY
|
-4.976x |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
0.010x |
|
WebRock Ventures AB
ST:WRV
|
-0.007x |
|
Industrial Minerals Ltd
AU:IND
|
-0.077x |
|
FENIXORO GOLD CORP.
F:8FD
|
N/A |
|
One SA
WAR:FMG
|
0.074x |
Annual Cash Flow Conversion Efficiency for Bioatla Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bioatla Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Bioatla Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-36.19 Million | $-48.20 Million | 1.332x | +126.41% |
| 2024-12-31 | $14.27 Million | $-71.94 Million | -5.043x | -242.63% |
| 2023-12-31 | $70.67 Million | $-104.02 Million | -1.472x | -193.54% |
| 2022-12-31 | $180.34 Million | $-90.42 Million | -0.501x | -69.90% |
| 2021-12-31 | $210.82 Million | $-62.21 Million | -0.295x | -70.54% |
| 2020-12-31 | $209.97 Million | $-36.33 Million | -0.173x | -200.49% |
| 2019-12-31 | $-56.01 Million | $-9.64 Million | 0.172x | -86.13% |
| 2018-12-31 | $-28.45 Million | $-35.32 Million | 1.242x | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more